Hanmi Science Subsidiary Hanmi Pharmaceutical Signs $1.26B GLP2 Technology Transfer Agreement with Eli Lilly - Significant Share Price Catalyst and Enterprise Value Upside
Sonefpeglutide (HM15912) Technology Transfer: Hanmi Pharmaceutical, a subsidiary of Hanmi Science, has entered into a global technology transfer agreement with Eli Lilly for a long-acting GLP2 analog (short bowel syndrome treatment). Total deal value up to $1.26 billion (approx. 1.90 trillion KRW), representing 87.5% of Hanmi Science's current market cap (~2.17 trillion KRW).
Upfront and Milestone Structure: Non-refundable upfront payment of $75 million (~113 billion KRW) immediately receivable, plus up to $1.185 billion (~1.78 trillion KRW) in development, regulatory, and commercialization milestones. Post-launch tiered royalties on annual net sales also included.
License Scope and Territory: Hanmi grants Lilly exclusive rights for development, manufacturing, and commercialization worldwide excluding South Korea. Leveraging Lilly's global clinical and marketing capabilities expected to accelerate market entry.
Impact on Enterprise Value and Shareholders: Short-term, the upfront payment strengthens Hanmi Science's financial position. Long-term, successful milestones and royalties could generate massive cash inflows. The partnership with Lilly also revalues the pipeline and opens doors for future deals, driving share price upside.
Investment Risks: Milestone payments are contingent upon clinical success, regulatory approvals, and sales performance; full realization is not guaranteed. South Korea is excluded from the deal, requiring separate commercialization strategy for domestic market.
[AI Summary]Hanmi Science's subsidiary Hanmi Pharmaceutical's $1.26B GLP2 technology transfer agreement with Eli Lilly is a massive positive catalyst, providing immediate non-refundable upfront cash ($75M) and significant long-term milestone/royalty potential, representing 87% of current market cap without equity dilution, thereby substantially enhancing shareholder value and justifying a re-rating of the company's enterprise value.
KOSPI Filing Information
Filing: Major Management Matters Related to Investment Decision (Major Management Matters of Subsidiary) (Conclusion of Technology Transfer Agreement for Sonefpeglutide (Sonefpeglutide; LAPS GLP2 Agonist; HM15912))